CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock



Company Profile

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	2 2	202	21
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	1,366,426,000,000		1,336,537,000,000		1,063,661,000,000	
Common stock capital		73,202,000,000		73,202,000,000		73,202,000,000
Fixed assets	566,121,000,000		533,221,000,000		475,033,000,000	
Equity capital of a company		1,625,580,000,000		1,424,387,000,000		1,188,017,000,000
Cash and cash equivalents	458,674,000,000		222,169,000,000		267,753,000,000	
Accrued liabilities		5,739,000,000		6,067,000,000		5,046,000,000
Other assets	-		-		-	
Current liabilities		288,217,000,000		423,730,000,000		327,422,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		18,749,000,000		21,641,000,000		23,255,000,000
Different income		-		-		-
Other liabilities		743,000,000		813,000,000		1,105,000,000
Total assets	1,932,547,000,000	1,932,547,000,000	1,869,758,000,000	1,869,758,000,000	1,538,694,000,000	1,538,694,000,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	7,604	7,771	7,664
Equity ratio	84.12%	76.18%	77.21%
Debt-equity ratio	18.88%	31.27%	29.52%

Others			
	2023	2022	2021
Tax Expense Rate	26.67%	29.51%	27.75%

CHUGAI PHARMACEUTICAL CO LTD

ISIN: JP3519400000 WKN: 4519 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	1,111,367,000,000	1,259,946,000,000	999,758,000,000
Net income	325,472,000,000	374,429,000,000	302,995,000,000
EBIT	2,741,175,000	3,292,472,800	2,599,461,600
Operating income before taxes	443,821,000,000	531,166,000,000	419,385,000,000
Cash Flow	411,326,000,000	244,335,000,000	279,711,000,000
Net interest income	1,696,000,000	122,000,000	117,000,000
Research and development expenses	164,764,000,000	148,360,000,000	131,276,000,000
Income taxes	118,349,000,000	156,737,000,000	116,390,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	906,165	1,005,233	808,781

Board of Directors

Christoph Franz	Member of Supervisory Board
James Sabry	Member of Supervisory Board
Iwaaki Taniguchi	Member of Supervisory Board
Mariko Momoi	Member of Supervisory Board
Masayuki Oku	Member of Supervisory Board
Motoo Ueno	Member of Supervisory Board
William Anderson	Member of Supervisory Board
Yoichiro Ichimaru	Member of Supervisory Board

Members of Management Board

Osamu Okuda	Chairman of Managing Board
Hitoshi Ikura	Member of Executive Committee
Iwaaki Taniguchi	Member of Executive Committee
Junichi Ebihara	Member of Executive Committee
Shinji Hidaka	Member of Executive Committee
Tetsuya Yamaguchi	Member of Executive Committee
Yoshiyuki Yano	Member of Executive Committee